{"name":"Blue Earth Therapeutics Ltd","slug":"blue-earth-therapeutics-ltd","ticker":"","exchange":"","domain":"blueearth.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxOaWJHTkVvd3diWm9pX3c0aEx4MnZfMmRmRkczT3g4ZkE1RmE4eU1Qd1JmSXBsVThCYUlib0dLNEt1M0tVOHlZNnBodFpuRngxM2kyOFBkOUlENlB6bUx4Q2NqUmY4ek02SmtlT1h6ZUQ0M29nYzJtVkNUTC01aEpyUkN5VXBSV3U4aDczQ0NqMVFWRjcwTHd4ejdFT3ZLTjNtaWdhT3pKNkYtWlY1REJaUEk0VWN4UjdLaWg5NFhtbkhqUXJCekhoWnB1RG5FTFRpOEttc1RwLVY1VGdQSlB6M2hlcC1KTENhSC01WWRtNXh4NnVCNDN3YkJTZURpOTg?oc=5","date":"2026-01-20","type":"pipeline","source":"PR Newswire","summary":"PSMA-Targeted Therapy Market Set to Expand by 2034 on Strong Pipeline and Increasing Diagnosis Rates | DelveInsight - PR Newswire","headline":"PSMA-Targeted Therapy Market Set to Expand by 2034 on Strong Pipeline and Increasing Diagnosis Rates | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-15","type":"pipeline","source":"PR Newswire UK","summary":"First Patients in the UK Receive Doses of Blue Earth Therapeutics' Investigational Radiopharmaceutical Therapy Lutetium (177Lu) rhPSMA-10.1 Injection for Metastatic Castrate Resistant Prostate Cancer ","headline":"First Patients in the UK Receive Doses of Blue Earth Therapeutics' Investigational Radiopharmaceutical Therapy Lutetium ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNSnNoZjh6OG0wWHNjNzVBc1h5RkJTRHlka2VGcFRwNzFjYUtBRkJSX2xuSWlLd0Vqd0VhSi01cnlwWGF4OGVaVW9YLXZUN0JQVkpFNGFURHJ0R2ozaDBBczlJZHJrYkZDWVV4OFozLTFvVER1TTNHWEtjVVlJNzdkRHNpLTdiMzZJcy1v?oc=5","date":"2026-01-08","type":"regulatory","source":"Yahoo Finance","summary":"Earth Harmony Ultimate Methylene Blue Addresses Consumer Demand for USP Pharmaceutical-Grade Verification in Mitochondrial Support Category - Yahoo Finance","headline":"Earth Harmony Ultimate Methylene Blue Addresses Consumer Demand for USP Pharmaceutical-Grade Verification in Mitochondri","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AJBVV95cUxPcG02MzkwN3FNRFZGZnFTVEZWUXpIaUtiYVBNMlFkVEVOLS1OTVhhcWVUM284VkR1T0FNQkNWM2hxWE9HUXlmX1ZUTTBsRWZpOFlGVVExT19vMy0tX2hPRXRaX3FoMEQ5MFR5MEx2TVBIYV9DeUw1Q21FVzBYcWpNdXFMRkZtTWxuNjl3ZlE4VEZhYklIV295alFMeml3RzF4WlEzX0RkdHNTdkV3eG9sUGFUYjVtenlIR1VnV1RCQ293blNONVhnUGRBY3c4bFpsdW5WZzFWeEdoM0QxN2gwZmxnTmRkanBmU2VZNE43cVRveDlWVW5hekNnV3NvZWpjbnlxYjFYRVh4dkpWLVFHeU9sNEZkdVJ5eUZWRWF6TFhqV3N4a054V3VnZEY1aGx2UmFwVEpkZEZoVy1QNklnWVo2X2hCc2lydjhYVHotS0VyT3I0ZVgwcnRkaUg0dGxZ?oc=5","date":"2026-01-05","type":"regulatory","source":"PR Newswire UK","summary":"Castration-sensitive Prostate Cancer Market Projected to Grow at a 13.2% CAGR (2020-2034), Driven by Expanded Approval and Wider Commercialization Opportunity in nmCSPC Segment | DelveInsight - PR New","headline":"Castration-sensitive Prostate Cancer Market Projected to Grow at a 13.2% CAGR (2020-2034), Driven by Expanded Approval a","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNT1VGV3pzWTctVWFZaGotZTJ2ZW1hSV9UTHZZVVZkX1dCYXJmNnZWZm5TcVluX3lFZmltRG44aWE0amZEOExqUG9abTYzU2RfQVN5NE5hT3RDdTBfMU5kazFrNURxTXZEak1NV2lSNjN3cFlfNFdjamVRZlcyQnpVU3hoVTMyUlFqSDV1ZW1FT3UtLUNkeEFGWmZUcFUwZGpkcEg2b3lB?oc=5","date":"2025-07-04","type":"regulatory","source":"Pharmafile","summary":"Johnson & Johnson seeks EMA approval to accelerate prostate cancer treatment - Pharmafile","headline":"Johnson & Johnson seeks EMA approval to accelerate prostate cancer treatment","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQblE3WmJsWEUzWlZ3Z3BvSzFDdmJkWU54aExXTlFjVnpoTU42aXAwMUMyb2Z3T3RlZHkxNWE3UjRmZ1h6Z1UyTXlfNUQ0ZEhJVGxWMEtHTW9GTENxR3dOV1k0ZDBjYnhoc3hvQkQ5dUJGaXc0U3lXeFFlX0R0ekJoQ3hTcU0wMDdndHdqci0tLUZyOWM0dWVJ?oc=5","date":"2025-07-01","type":"trial","source":"Imaging Technology News","summary":"Multimodal AI Shows No Evidence of Bias in Prostate Cancer Study - Imaging Technology News","headline":"Multimodal AI Shows No Evidence of Bias in Prostate Cancer Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPTy1GZnE0YUlscHp5a2Y1b0Nwc3VmVWd2ME12Rl9KczdfRWZqMlB4dHFsRVBXRHlLelk3b045RFNJVlBKa0ZLZVdUVGVWMWxJMmxqN0hLdC1WTGNuc1RHN1lMcktWNjJvejkyY0RLR2l5MmI4cElXc0pxdWtRRFBDVzBPRGgzR3VXV05xQ2FULWVKZDFPR2J3RkVDUkNjMDJfdVk5b240T1dVUHRHYmdRUms1VkRMakgtN2ItN0pxM3N3UHR1clA5NnlUMW9KWm12RS1GRHZ0TGJoWXM3Qmc?oc=5","date":"2025-05-22","type":"trial","source":"Pharmafile","summary":"Another Day Pharma announces successful Phase II trial results for BZ371A in post-prostatectomy erectile dysfunction - Pharmafile","headline":"Another Day Pharma announces successful Phase II trial results for BZ371A in post-prostatectomy erectile dysfunction","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi1wJBVV95cUxNSDhsVUtYMGhUQTJ5Q0ZCSUZHZ25qTk9KMTBHNjZkNndfOU9Lb2VpbUt1Z0pDcDgzT0ZaeEU1UXIyRjk2eGZqNUdCN1FQc2pGakREX2Z4RTdWakdMQ2MtWFJBeU10TXEtWXlIZkpncEZqU1pzUlFMcEd1SmZuZ2o5WFZDcDJHM2o5b2hDcW9hTEhwMU94Y3F6cUk0dC1PQmEzRUpRbzliOEhud0ZBbVhwUWRzYml1THBhVG0zZWtJRFFaajNvb19KMGpOSjNKM2RrOVRVdS1GUkJzQnJtdFQ2ZldSc2lBRzdWejdZTGdNRkNHQTJFa2RZX2pyc3ZVSEJNbFpmSzNmVGVtMzZONWU0QzNNZjNEd3hGOGxvVzJfUjcwOXVYSkdVU0xpcDd3T3pCVm1TRkVYN21yMTFHU29pOGdVRmlDQXRqUkhwcE9HYVNQRXAyV0hn?oc=5","date":"2025-05-01","type":"trial","source":"PR Newswire","summary":"Blue Earth Therapeutics initiates Phase 2 Clinical Trial evaluating the efficacy and safety of Lutetium (177Lu) rhPSMA-10.1 Injection in metastatic castrate resistant prostate cancer - PR Newswire","headline":"Blue Earth Therapeutics initiates Phase 2 Clinical Trial evaluating the efficacy and safety of Lutetium (177Lu) rhPSMA-1","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNckRsRGFjMV90RUU3TlluUGFHbHN5V0NSYWg0WGJ6a09HdnYySzhvaHRERVFnWUJkUmp2UG82S0prVmdSLV9CRnZWOTh6dWVEVVdEdXZETFYwUDNkSm0tcjVrQkl5TVFzM0JJR2VCb3NBUnZFdF91RFA5WHFRS2YwNnNmN0l2OXA2dWtnX25FS3RfWjNIUWsySTdVcm9ka1dPV3ZIbG1DUzE0SHppSUxjdWxCWlY?oc=5","date":"2024-11-01","type":"trial","source":"Imaging Technology News","summary":"Blue Earth Therapeutics Reports Promising Phase 1 Data for Investigational Therapies - Imaging Technology News","headline":"Blue Earth Therapeutics Reports Promising Phase 1 Data for Investigational Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxQd0tBV25aWnlpREVyMEJvNTYyYkQ1N2xDVXFKcVZGdFhMaVlWVHp6RHRJVUFFZGhfOTJYRjZGdm5vY0cyZG5EYW5ud0RhOW42UERMQldwR0hwaXp5a09wUjJHUmpucjFmSnJjQmtON2pkV1BwT0loTXZXN3U2MGN0Y2JwSkp2c1BHMUJYdjdyTXRGVVdaTDhEVG5MM1o3bWxFWWhXYW5TRGxrc3JQa0pYeHZvcl9Cd2FST2VpOF9ILThIWFdaRFJBN3ZScEp0bUk0TkNaVDhMSG9XTU9MMW5kem5MMlRfT05hSlpKcURwcG9fVXJ5eG9nSG4zdVNlMTJFS3A4ODRCeE9tcVlWeU5PNHBBcUoySU1vWDVDSDVMQ3Z0VHJoWnFEZXJlbHJYYlNfUUE?oc=5","date":"2024-10-30","type":"pipeline","source":"PR Newswire","summary":"Blue Earth Therapeutics Ltd announces completion of $76.5M Series A financing to accelerate development of next generation targeted radioligand therapies - PR Newswire","headline":"Blue Earth Therapeutics Ltd announces completion of $76.5M Series A financing to accelerate development of next generati","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxNYnlrT0hIc1djR2UzT1h4QngzTWZGdnc3U0hjaEIyTjZWN0I3Umh3SHJQN2pfcHU1bWJTQl9Deks5QXVhZDE4Q0tvVldsYV9jamZpYnVKd0RBRnhvd0tHYzMxS2lIbTBnMTBwMTZQUzdJOGNQdUpIcWU5VzhuazdDSEU2UTRoM3o2TnpQczdzZDVQM2VOVzZaSkl6RlJjaXJKVGl3emZGVUItQkFFMWJFYjJ2MUdiWFdkR2xycGE4ZzZzVllieUNPQlctRTAyaTJiNGtoei1CM2tVZEdFeV9Xa25GSWxUZUFJeDI0enhNb3Q5Sk5rQVRBd0VSckRCZGtXRmxIZ2IwSHBES1VGVVdDclAwdjlmV1F3Sy1TYmxzbHgzMHJOVjI1YU9pNHBWX0kyYWJoV1JHUQ?oc=5","date":"2024-07-23","type":"regulatory","source":"Business Wire","summary":"Blue Earth Therapeutics Announces Clinical Research Collaboration with UCL to Develop Innovative Alpha-labelled Radioligand Therapy (RLT) for Prostate Cancer - Business Wire","headline":"Blue Earth Therapeutics Announces Clinical Research Collaboration with UCL to Develop Innovative Alpha-labelled Radiolig","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPZFZDSkM3bmpTQ1RsNm43R0tBOW1WMGNlYmxIRmdheVFoMG5MWHZCSkhCRC1PamxyV2ZQeUNQb2owZGwxT0ttMmJQdUZBV21xWmNFV2taNWVYRUp6RW1CdEcwdEI0bkJXQkhwaTFtMnMtZ2tXREpmdEd0T3RzeVR2RlVWRngtYWN6Z0dwaXVITjIxUU9UVkkyZnFaTFI0dHducVY0MGdnSnU5OWtfZ3c?oc=5","date":"2024-07-08","type":"pipeline","source":"citybiz","summary":"Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as CEO - citybiz","headline":"Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as CEO","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}